Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Wynick

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Neuropeptides|October 3, 2002
Targeted disruption of galanin: new insights from knock-out studiesD Wynick, A Bacon
Health Trends|January 10, 1985
A survey of cost awareness among hospital medical staffD Wynick, J H Jessop
The British Journal of Nutrition|March 1, 1981
Inhibition of kynureninase (L-kynurenine hydrolase, EC 3 . 7. 1 . 3) by oestrone sulphate: an alternative explanation for abnormal results of tryptophan load tests in women receiving oestrogenic steroidsD A Bender, D Wynick
British Medical Journal (Clinical Research Ed.)|November 21, 1987
Effect of calcitonin in patients with malignant metastatic islet cell tumorsD Wynick, S R Bloom
Neuroendocrinology|December 1, 1990
Magnetic bead separation of anterior pituitary cellsD Wynick, S R Bloom
The Journal of Clinical Endocrinology and Metabolism|July 1, 1991
Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumorsD Wynick, S R Bloom
Digestion|January 1, 1990
Sandostatin and the Hammersmith experienceD Wynick, S R Bloom
Neuropeptides|June 10, 2005
Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injuryF E Holmes, S-A Mahoney, D Wynick
Neuroreport|December 16, 2000
Galanin-like peptide (GALP) is expressed in rat hypothalamus and pituitary, but not in DRGN C Kerr, F E Holmes, D Wynick
The New England Journal of Medicine|September 8, 1988
Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumorsD Wynick, S J Williams, S R Bloom
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Neuropeptides|October 3, 2002
Targeted disruption of galanin: new insights from knock-out studiesD Wynick, A Bacon
Health Trends|January 10, 1985
A survey of cost awareness among hospital medical staffD Wynick, J H Jessop
The British Journal of Nutrition|March 1, 1981
Inhibition of kynureninase (L-kynurenine hydrolase, EC 3 . 7. 1 . 3) by oestrone sulphate: an alternative explanation for abnormal results of tryptophan load tests in women receiving oestrogenic steroidsD A Bender, D Wynick
British Medical Journal (Clinical Research Ed.)|November 21, 1987
Effect of calcitonin in patients with malignant metastatic islet cell tumorsD Wynick, S R Bloom
Neuroendocrinology|December 1, 1990
Magnetic bead separation of anterior pituitary cellsD Wynick, S R Bloom
The Journal of Clinical Endocrinology and Metabolism|July 1, 1991
Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumorsD Wynick, S R Bloom
Digestion|January 1, 1990
Sandostatin and the Hammersmith experienceD Wynick, S R Bloom
Neuropeptides|June 10, 2005
Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injuryF E Holmes, S-A Mahoney, D Wynick
Neuroreport|December 16, 2000
Galanin-like peptide (GALP) is expressed in rat hypothalamus and pituitary, but not in DRGN C Kerr, F E Holmes, D Wynick
The New England Journal of Medicine|September 8, 1988
Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumorsD Wynick, S J Williams, S R Bloom
Pageof 5